Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2008 Aug 5

PMID 18672949

Citations 955

Authors

Frank Alexis

Eric Pridgen

Linda K Molnar

Omid C Farokhzad

Affiliations

Soon will be listed here.

Abstract

Nanoparticle (NP) drug delivery systems (5-250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biological barriers and releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating nanoparticles during systemic delivery is a critical issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life. In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation. These factors include interactions with biological barriers and tunable nanoparticle parameters, such as composition, size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization. All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.

Citing Articles

Nano-formulated curcumin uptake and biodistribution in the fetal growth restricted newborn piglet brain.

Xu N, Wixey J, Chand K, Wong M, Nance E Drug Deliv Transl Res. 2025; .

PMID: 40053231 DOI: 10.1007/s13346-025-01830-y.

Advances in RNAi-based nanoformulations: revolutionizing crop protection and stress tolerance in agriculture.

Mathur S, Chaturvedi A, Ranjan R Nanoscale Adv. 2025; .

PMID: 40046252 PMC: 11877354. DOI: 10.1039/d5na00044k.

C hyperpolarization with nitrogen-vacancy centers in micro- and nanodiamonds for sensitive magnetic resonance applications.

Blinder R, Mindarava Y, Korzeczek M, Marshall A, Glockler F, Nothelfer S Sci Adv. 2025; 11(9):eadq6836.

PMID: 40020059 PMC: 11870072. DOI: 10.1126/sciadv.adq6836.

Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system.

Karimi M, Dehdari Vais R, Karimian K, Parsaei A, Heli H Ther Deliv. 2025; 16(3):237-246.

PMID: 39991842 PMC: 11875489. DOI: 10.1080/20415990.2025.2466412.

Biodistribution of Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through PET Imaging.

Lopez-Estevez A, Carrascal-Minino A, Torres D, Alonso M, T M de Rosales R, Pellico J ACS Omega. 2025; 10(5):4763-4773.

PMID: 39959112 PMC: 11822718. DOI: 10.1021/acsomega.4c09823.

References

Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W . PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001; 71(2):203-11. DOI: 10.1016/s0168-3659(01)00218-8. View

Farokhzad O, Jon S, Khademhosseini A, Tran T, LaVan D, Langer R . Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64(21):7668-72. DOI: 10.1158/0008-5472.CAN-04-2550. View

Meerum Terwogt J, Ten Bokkel Huinink W, Schellens J, Schot M, Mandjes I, Zurlo M . Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001; 12(4):315-23. DOI: 10.1097/00001813-200104000-00003. View

Kirk S, Frank J, Karlik S . Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J Neurol Sci. 2004; 217(2):125-30. DOI: 10.1016/j.jns.2003.10.016. View

Rice J, Gerberich J, Nowotnik D, Howell S . Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006; 12(7 Pt 1):2248-54. DOI: 10.1158/1078-0432.CCR-05-2169. View

Clauss M, Jain R . Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 1990; 50(12):3487-92. View

Alexis F, Rhee J, Richie J, Radovic-Moreno A, Langer R, Farokhzad O . New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008; 26(1):74-85. DOI: 10.1016/j.urolonc.2007.03.017. View

Sun X, Rossin R, Turner J, Becker M, Joralemon M, Welch M . An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules. 2005; 6(5):2541-54. PMC: 2533516. DOI: 10.1021/bm050260e. View

Romberg B, Hennink W, Storm G . Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2007; 25(1):55-71. PMC: 2190344. DOI: 10.1007/s11095-007-9348-7. View

10.

Kim T, Kim D, Chung J, Shin S, Kim S, Heo D . Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10(11):3708-16. DOI: 10.1158/1078-0432.CCR-03-0655. View

11.

Li C, Newman R, Wu Q, Ke S, Chen W, Hutto T . Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol. 2000; 46(5):416-22. DOI: 10.1007/s002800000168. View

12.

Posey 3rd J, Saif M, Carlisle R, Goetz A, Rizzo J, Stevenson S . Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2005; 11(21):7866-71. DOI: 10.1158/1078-0432.CCR-05-0783. View

13.

Soepenberg O, de Jonge M, Sparreboom A, de Bruin P, Eskens F, de Heus G . Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res. 2005; 11(2 Pt 1):703-11. View

14.

Pridgen E, Langer R, Farokhzad O . Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond). 2007; 2(5):669-80. DOI: 10.2217/17435889.2.5.669. View

15.

Kommareddy S, Amiji M . Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci. 2006; 96(2):397-407. DOI: 10.1002/jps.20813. View

16.

Ludatscher R, Stehbens W . Vesicles of fenestrated and non-fenestrated endothelium. Z Zellforsch Mikrosk Anat. 1969; 97(2):169-77. DOI: 10.1007/BF00344755. View

17.

Takeoka S, Teramura Y, Okamura Y, Tsuchida E, Handa M, Ikeda Y . Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions. Biochem Biophys Res Commun. 2002; 296(3):765-70. DOI: 10.1016/s0006-291x(02)00934-8. View

18.

Conover C, Greenwald R, Pendri A, Gilbert C, Shum K . Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol. 1998; 42(5):407-14. DOI: 10.1007/s002800050837. View

19.

Graff C, Wittrup K . Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003; 63(6):1288-96. View

20.

Predescu D, Palade G . Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. Am J Physiol. 1993; 265(2 Pt 2):H725-33. DOI: 10.1152/ajpheart.1993.265.2.H725. View